Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Calemma, Rosa ^a   Ottaiano, Alessandro ^a   Trotta, Anna M ^a   Nasti, Guglielmo ^a   Romano, Carmela ^a   Napolitano, Maria ^a   Galati, Domenico ^a   Borrelli, Pasquale ^a   Zanotta, Serena ^a   Cassata, Antonino ^a   Castello, Giuseppe ^b   Iaffaioli, Vincenzo R ^a   Scala, Stefania ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CROM Centro Ricerche Oncologiche di Mercogliano   (Italy)

Author keywords

Antibody dependent cell mediated cytotoxicity; Cetuximab; Colorectal cancer; Fc gamma receptor; Panitumumab; Prognosis

Indexed keywords

ARGININE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FC GAMMA IIIA; FC RECEPTOR; FC RECEPTOR IIA; FLUOROURACIL; HISTIDINE; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PHENYLALANINE; UNCLASSIFIED DRUG; VALINE;

ACNE; ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DERMATITIS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OUTCOME ASSESSMENT; PALLIATIVE THERAPY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, IGG; TREATMENT OUTCOME;

EID: 84869221346     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-232     Document Type: Article

References (20)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236. 10.3322/caac.20121, 21685461.
2. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin Oncol 2011, 38:552-5560. 10.1053/j.seminoncol.2011.05.009, 21810514.
3. Tol J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 2010, 32:437-453. 10.1016/j.clinthera.2010.03.012, 20399983.
4. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010, 28:1254-1261. 10.1200/JCO.2009.24.6116, 20100961.
5. Ottaiano A, Scala S, Iaffaioli RV. Cetuximab-dependent ADCC in cancer: dream or reality?. Cancer Immunol Immunother 2010, 59:1607-1608. 10.1007/s00262-010-0884-3, 20577878.
6. Correale P, Marra M, Remondo C, et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010, 46:1703-1711. 10.1016/j.ejca.2010.03.005, 20399639.
7. Bier H, Hoffmann T, Haas I, van Lierop A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity 19 against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 1998, 46:167-173. 10.1007/s002620050475, 9625540.
8. García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010, 12:533-542. 10.1007/s12094-010-0551-3, 20709651.
9. McKenzie SE, Schreiber AD. Biological advances and clinical applications of Fc receptors for IgG. Curr Opin Hematol 1994, 1:45-52.
10. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD2 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIIa gene. Blood 2002, 99:754-758. 10.1182/blood.V99.3.754, 11806974.
11. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003, 21:3940-3947. 10.1200/JCO.2003.05.013, 12975461.
12. Carlotti E, Palumbo GA, Oldani E, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007, 92:1127-1130. 10.3324/haematol.11288, 17650444.
13. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957, 18347005.
14. Zhang W, Gordon M, Schultheis AM, et al. Fc R2A and Fc R3A Polymorphisms associated with clinical outcome of epidermal growth factor receptor-expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718. 10.1200/JCO.2006.08.8021, 17704420.
15. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of Fc RIIa-Fc RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-1129. 10.1200/JCO.2008.18.0463, 19164213.
16. Carotenuto P, Roma C, Cozzolino S, et al. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR. Int J Oncol 2012, 40:378-384.
17. Jiang XM, Arepally G, Poncz M, McKenzie S. Rapid detection of the FcyRIIA-H/R131 ligand-binding polymorphism using an allele-specific restriction enzyme digestion (ASRED). J Immunol Methods 1996, 199:55-59. 10.1016/S0022-1759(96)00164-0, 8960098.
18. de Straat FG L-V, van der Pol WL, Jansen MD, et al. A novel PCR-based method for direct Fc gamma receptor IIIa (CD16) allotyping. J Immunol Methods 2000, 242:127-132. 10.1016/S0022-1759(00)00240-4, 10986395.
19. Overdijk MB, Verploegen S, van den Brakel JH, et al. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol 2011, 187:3383-3390. 10.4049/jimmunol.1003926, 21832160.
20. Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012, 30:2861-2868. 10.1200/JCO.2011.40.9243, 22753904.